Login to Your Account

Orphan Europe, Erytech Ink Deal for New Asparaginase

By Cormac Sheridan
Staff Writer

Tuesday, December 4, 2012
A recent European licensing deal between Orphan Europe and Erytech Pharma SA on a novel formulation of asparaginase, called Graspa, is further evidence of the commercial revitalization of a long-established treatment in hematologic cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription